GRML

GRML is not a company you can underwrite—it's a shell that has changed its identity four times in under three years: Redwoods Acquisition Corp → ANEW Medical → Klotho Neurosciences → Greenland Mines Ltd (ticker changed to GRML on Nasdaq only on 2026-03-12). The financials presented are those of the accounting acquirer (ANEW Medical, a gene-therapy/biosimilar developer) via reverse merger, yet the entity just renamed itself 'Mines' and in March 2026 closed an acquisition of Greenland Mines Corp that the MD&A explicitly says is NOT reflected in these numbers and 'may be material.' You are therefore looking at the audited history of one business while the market prices a completely different, undisclosed one. That is unknowable risk by definition.

The fundamentals under the hood are pre-revenue and deteriorating. The company states plainly it 'has not generated any operating revenues to date'—no revenue in FY2025, FY2024, or any prior year. The FY2025 net loss widened to -$10.6M (from -$6.15M), operating loss -$7.15M, and operations burned -$5.89M of cash. Against $7.18M of cash, that is roughly a single year of runway before another raise. ROE is -111.5% on an accumulated deficit of -$21.1M. The one genuinely clean line—liabilities/equity of 0.01x and $9.46M equity—exists only because shares outstanding ballooned +325% to 121M, i.e. the balance sheet was 'repaired' entirely by dilution, not by the business. Cash up 11,159% YoY tells the same story: this is financing inflow, not earned value.